XXII 22nd Century Group Inc.

22nd Century Group (XXII) Announces Production of VLN® Homogenized Tobacco Leaf Sheet

22nd Century Group (XXII) Announces Production of VLN® Homogenized Tobacco Leaf Sheet

HTL Is Commonly Used in Heat-Not-Burn and Cigar Binder and Wrapper Applications

Provides VLN® Tobacco Solution in Large Adjacent Markets

BUFFALO, N.Y., June 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced it has successfully produced homogenized tobacco leaf (HTL) sheet using VLN® reduced nicotine content tobacco, demonstrating a reduced nicotine content pathway for additional large markets such as heat-not-burn products and as the binder or wrapper for machine-made cigars.

“It’s time for the industry to offer adult smokers a true alternative to highly addictive nicotine products in every format. HTL is critical to the fast-growing heat-not-burn product category, where a VLN® 95% reduced nicotine content HTL would be a compelling alternative to the nicotine-laden tobaccos commonly used in these products. HTL is also commonly used as the binder and wrapper in the high-volume cigar market due to its greater mechanical resistance and uniformity as compared to whole tobacco leaves,” stated John Miller, president of tobacco products for 22nd Century Group.

The global heat-not-burn market is estimated to exceed $24 billion by 2027 according to Research and Markets estimates. The global cigar market is expected to reach $114 billion by 2030, according to Straits Research, with the bulk being machine made products using HTL.

“Conventional tobacco products still seek to create and sustain nicotine addiction to generate sales. Even alternatives to conventional smoking products, such as vaping and e-cigarettes, perpetuate sales through nicotine addiction rather than giving consumers a real choice. 22nd Century wants to provide a true alternative that allows users to take control of their consumption habit once and for all by breaking the chains of nicotine addiction,” said James A. Mish, chief executive officer of 22nd Century Group.  

VLN® HTL sheet product could be manufactured and sold as a raw material input or produced under license for companies interested in offering reduced nicotine content and non-addictive products, providing an off-ramp for adult smokers seeking to take control of their smoking habit and nicotine consumption.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading biotechnology company focused on utilizing advanced alkaloid plant technologies to improve health and wellness through tobacco harm reduction, reduced nicotine tobacco, hemp/cannabis and hops. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. In tobacco, hemp/cannabis and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at , on , on , and on .

Learn more about VLN® at .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 9, 2023. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Matt Kreps

Investor Relations

22nd Century Group



214-597-8200



EN
23/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

Emerging Growth Research Releases Quarterly Update Report on 22nd Cent...

Sheridan, Wyoming--(Newsfile Corp. - April 10, 2025) - Emerging Growth Research is pleased to release its latest quarterly update on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q4 2024 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.To read the full report, please visit: Q4 2024 Financial Highlights:Revenue was $4.0 million, down 45% YoY, reflecting expected attrition due to CMO contract price hikes. Gross profit improved YoY to $(1.3) million from $(7.8) million. Opera...

 PRESS RELEASE

Emerging Growth Research Releases New Initiation Report on the 22nd Ce...

Sheridan, Wyoming--(Newsfile Corp. - February 19, 2025) - Emerging Growth Research is pleased to announce the release of its new initiation report on the 22nd Century Group, Inc. (NASDAQ: XXII). The Company has made significant strides in its operational and financial restructuring under new management, with only the warrant overhang remaining to be addressed. To read this report, please visit XXII's landing page on the Emerging Growth website, located here: .XXII's new management has successfully reduced operating cash losses in the first nine months of 2024 and further decreased the Company'...

 PRESS RELEASE

22nd Century Secures $3.2 Million to Date in Warrant Exchange Transact...

22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction Newly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce Costs BUFFALO, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the exercise of warrants by certain holders pursuant to its previously announced warrant inducement offering. During the inducement period, certain holders of the Company’s existing warrants acqui...

 PRESS RELEASE

22nd Century Appoints Larry Firestone as Chairman and CEO

22nd Century Appoints Larry Firestone as Chairman and CEO Turnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco Assets BUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (“22nd Century” or the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, “Larry is a seasoned executive known for his 'hands-on...

 PRESS RELEASE

22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchi...

22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements BUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ) (the “Company” or “22nd Century”), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has reached an agreement to sell substantially all of its GVB Biopharma (“GVB”) hemp/cannabis operations to Specialty Acquisition Corporation, a Nevada corporation ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch